Topic: Health
Researchers at UC San Francisco have developed a new method to reprogram immune cells inside the body to fight cancer. This approach could make CAR-T cell therapy more accessible and affordable for patients.
CAR-T cell therapy has been a game-changer in treating certain blood cancers, but it's not without its challenges. The process of collecting a patient's immune cells, sending them to a specialized facility, and then infusing the engineered cells back into the patient is complicated, expensive, and slow. It can take weeks and cost hundreds of thousands of dollars.
Researchers at UC San Francisco have now developed a potential alternative that could change this. They've created a system that uses CRISPR-Cas9 gene-editing machinery to deliver new instructions directly to T cells inside the body. This approach, called in vivo manufacturing, could make it possible to produce engineered immune cells without the need for expensive and time-consuming facilities.
The team successfully tested their method against aggressive leukemia, multiple myeloma, and even a solid tumor in mice with humanized immune systems. They inserted a large stretch of DNA into a precise location in human T cells without removing them from the body. This targeted technique performed better than using viruses to insert DNA at random locations.
The researchers are excited about the potential implications of this breakthrough. 'I think this is just the beginning of a big wave of new therapies that will be truly transformational and save a lot of lives,' said Justin Eyquem, PhD, an associate professor of medicine at UCSF.
Why It Matters
This breakthrough could make CAR-T cell therapy more accessible and affordable for patients in India who are struggling with blood cancers. It's a significant step forward in the fight against cancer, and it could save countless lives.
Key Facts
- Researchers at UC San Francisco have developed a new method to reprogram immune cells inside the body to fight cancer.
- The approach uses CRISPR-Cas9 gene-editing machinery to deliver new instructions directly to T cells.
- The team successfully tested their method against aggressive leukemia, multiple myeloma, and even a solid tumor in mice with humanized immune systems.
- This breakthrough could make CAR-T cell therapy more accessible and affordable for patients.
- Justin Eyquem, PhD, is the senior author of the new paper and an associate professor of medicine at UCSF.
Key Terms
- CAR-T cell therapy
- A type of cancer treatment that uses genetically modified immune cells to attack cancer cells.
- CRISPR-Cas9 gene-editing machinery
- A tool used to edit genes and deliver new instructions to cells.
Implications
This breakthrough could make CAR-T cell therapy more accessible and affordable for patients in India who are struggling with blood cancers. It's a significant step forward in the fight against cancer, and it could save countless lives.
Leave a comment